Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-blind, Placebo Controlled, Single Ascending and Repeat Dose, First Time in Human Study in Healthy Participants and Stable Asthmatics to Assess Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder

NCT04585009 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04585009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04585009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-blind, Placebo Controlled, Single Ascending and Repeat Dose, First Time in Human Study in Healthy Participants and Stable Asthmatics to Assess Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
October 12, 2020
Completion date
June 16, 2022
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive